Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Tightens Control On New Pharmaceutical Entrants

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has announced it will tighten the admittance criteria of pharmaceutical companies and products, while at the same time encourage enterprises to merge for better competitiveness. Currently, an industry with an excessive number of players has given rise to unhealthy competition, allowing opportunistic counterfeiters to slip in unsafe low-quality drugs and drive up prices. In the last one-and-a-half years, the government cancelled 27 drug and medical device production licenses, withdrew 157 drug GMP certificates, and ordered 370 manufacturers to suspend production until rectification was carried out. SFDA is joining forces with the department of development and reform to set up policies for large-scale pharmaceutical production to ensure product quality and safety. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel